The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance

Vascular endothelial growth factor (VEGF) has become a major target in cancer treatment as it promotes tumor angiogenesis. Therapy with anti-VEGF antibody bevacizumab reportedly induces high levels of circulating VEGF which may potentially contribute to resistance. Based on animal or computational m...

Descripción completa

Detalles Bibliográficos
Autores principales: Alidzanovic, Lejla, Starlinger, Patrick, Schauer, Dominic, Maier, Thomas, Feldman, Alexandra, Buchberger, Elisabeth, Stift, Judith, Koeck, Ulrike, Pop, Lorand, Gruenberger, Birgit, Gruenberger, Thomas, Brostjan, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302983/
https://www.ncbi.nlm.nih.gov/pubmed/27527865
http://dx.doi.org/10.18632/oncotarget.11084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302983/
https://www.ncbi.nlm.nih.gov/pubmed/27527865
http://dx.doi.org/10.18632/oncotarget.11084

Ejemplares similares